

# Interface and Formulary Update - Issue 40

## January 2026

### Key messages from January 2026 TAG meeting - (ratified by Medicines Optimisation Programme Board)

#### Formulary Review – Pill in a Pocket - Flecainide

- Treatment for Paroxysmal Atrial Fibrillation
- Patient only takes when they experience an attack or episode
- Members confirmed that this practice is common and generally accepted by cardiologists, with no significant pushback from GP
- **Amber Initiative**

#### Formulary Review - Sparsentan for treatment of adults with primary immunoglobulin A nephropathy (IgAN) with a urine protein excretion $\geq 1.0$ g/day (or urine protein-to-creatinine ratio $\geq 0.75$ g/g) as per [TA1074](#)

- There is a limited patient population. To be reviewed if use expands.
- **RED - Restricted Use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care**

#### Formulary Review – EURneffy® for emergency treatment of severe allergic reactions due to insect stings or bites, food, medicinal products and other allergens, and idiopathic or exercise-induced anaphylaxis, in adults and children $\geq 30$ kg

- Adrenaline nasal spray which offers an alternative to current adrenaline auto-injector formulary options
- Useful for needle-phobic patients who meet criteria for use
- **BLACK – Not Commissioned. No prescribing in primary or secondary care recommendation** pending outcome of regional work by PAC

#### Pathway Review – Migraine routine update

- Use of topiramate in pregnancy is contra-indicated for migraine prophylaxis

### Updates from Prescribing Formulary Group

#### Dexamethasone preservative-free eye drops – 0.3ml

- Replace 0.5ml generic requests with new 0.3ml preparation
- Keep 0.4ml branded preparation on formulary as additional option in case of sensitivities to excipients or supply issues

#### Vizilatan Duo 50 micrograms/ml + 5 mg/ml eye drops, preservative-free (latanoprost/timolol) – multi-dose eye drop

- **Amber Advice** - second line for patients who are intolerant / allergy to preservatives

#### Eroxon Gel for use in erectile dysfunction

- Available OTC. High cost on FP10
- Limited evidence. **BLACK - Not for NHS prescribing**

#### LoFric Elle Intermittent Catheters

- Non-formulary product - **BLUE** classification in interim pending full review

#### Epilepsy formulary review

- Existing arrangements reviewed, updated and formalised so that Netformulary section can go live

## Traffic Light Additions / Updates (to be read in conjunction with [TAG Agreement document](#))

RED	<a href="#">TA1106 – November 2025 - Cabotegravir (Apretude®) for preventing HIV-1 in adults and young people (Commissioned by local authorities)</a>
	<a href="#">TA1109 – November 2025 - Darolutamide (Nubeqa®) with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer</a>
	<a href="#">TA1110 – November 2025 - Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer Replaces TA721</a>
	<a href="#">TA1113 – December 2025 - Glocitamab (Columvi®) with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma</a>
	<a href="#">TA1114 – December 2025 - Talquetamab (Talvey®) for treating relapsed and refractory multiple myeloma after 3 or more treatments</a>
	<a href="#">TA1115 – December 2025 - Vutrisiran (Amvuttra®) for treating transthyretin amyloidosis with cardiomyopathy</a>
	<a href="#">TA1116 – December 2025 - Obecabtagene autoleucel (obe-cel; Aucatzyl®) for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemia</a>
BLACK	<a href="#">TA1117 – December 2025 - Dostarlimab (Jemperli®) with platinum-containing chemotherapy for treating primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency</a>
	<a href="#">TA1108 – November 2025 - Cemiplimab (Libtayo®) with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer</a>
	<a href="#">TA1111 – November 2025 - Nintedanib for treating fibrosing interstitial lung disease in people 6 to 17 years (terminated appraisal)</a>
NICE - Approved	<a href="#">TA1112 – November 2025 - Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments (terminated appraisal)</a>
	<a href="#">TA1107 – November 2025 - Delgocitinib (Anzuppo®) for treating moderate to severe chronic hand eczema</a>

### Useful Information

<b>Next TAG meeting</b>	<b>Wednesday 4<sup>th</sup> March 2026</b>
<b>Deadline for agenda items</b>	<b>Tuesday 24<sup>th</sup> February 2026</b>
<b>Netformulary</b>	<a href="#">Norfolk and Waveney Formulary (norfolkandwaveneyformulary.nhs.uk)</a>
<b>Knowledge NoW – MO Team pages</b>	<a href="#">Prescribing, Pharmacy and Medicines Optimisation - Knowledge NoW (nwknowledgenow.nhs.uk)</a>
<b>TAG Guidance</b>	<a href="#">Therapeutic Advisory Group (TAG) and Commissioning - Knowledge NoW (nwknowledgenow.nhs.uk)</a>
<b>Shared Care Agreements</b>	<a href="#">Shared Care Agreements - Knowledge NoW (nwknowledgenow.nhs.uk)</a>
<b>Pathways and Prescribing Guidance</b>	<a href="#">Pathways and Prescribing Guidance - Knowledge NoW (nwknowledgenow.nhs.uk)</a>
<b>Practice Support</b>	<a href="#">Practice Support - Knowledge NoW (nwknowledgenow.nhs.uk)</a>
<b>Useful Links</b>	<a href="#">Useful Links - Knowledge NoW (nwknowledgenow.nhs.uk)</a>
<ul style="list-style-type: none"> <li><b>Please remember to check both <a href="#">KNoW</a> and <a href="#">Netformulary</a> for regular formulary updates</b></li> <li>If you have any interface or formulary queries, please send to the inbox - <a href="mailto:nwicb.medsqueries@nhs.net">nwicb.medsqueries@nhs.net</a></li> </ul>	